Presilium Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Presilium Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Hold	2,137	–	–	0.16%	37
2026 Q1	$954K	Buy	2,137 +10	+0.5%	+$4.66K	0.17%	35
2025 Q4	$964K	Buy	2,127 +3	+0.1%	+$1.29K	0.18%	36
2025 Q3	$832K	Hold	2,124	–	–	0.16%	38
2025 Q2	$946K	Hold	2,124	–	–	0.19%	33
2025 Q1	$1.03M	Hold	2,124	–	–	0.23%	32
2024 Q4	$855K	Sell	2,124 -6	-0.3%	-$2.78K	0.2%	39
2024 Q3	$991K	Hold	2,130	–	–	0.23%	35
2024 Q2	$998K	Buy	+2,130	New	+$925K	0.25%	33

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Presilium Private Wealth's VRTX Position: Q2 2026 in Review

Presilium Private Wealth held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 2,137 shares worth $1.06M. The position accounts for 0.16% of the portfolio, ranked #37.

Presilium Private Wealth first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Presilium Private Wealth held 2,137 shares of Vertex Pharmaceuticals worth $1.06M as of Q2 2026.
Presilium Private Wealth left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.16% of Presilium Private Wealth's portfolio in Q2 2026, its #37 holding.
Presilium Private Wealth first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Presilium Private Wealth's 13F filing for Q2 2026, filed 22 Jul 2026.